PGEN — PRECIGEN, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356090 ·
Last close
$7.81
Market Cap
$2.80B
52W High
$8.27
52W Low
$2.99
ADV30
4,720,365
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 54,978,000 | 52,173,000 | 22,642,000 | 20,071,000 | 170,296,000 | 16,329,000 | 126,720,000 |
| Mar 2026 | 23,252,000 | 20,693,000 | -5,994,000 | -7,929,000 | 138,627,000 | 7,480,000 | 118,392,000 |
| Dec 2025 | 4,565,000 | 2,969,000 | -21,666,000 | -23,503,000 | 155,505,000 | 30,234,000 | 134,594,000 |
| Sep 2025 | 2,922,000 | 1,887,000 | -34,481,000 | -146,344,000 | 171,264,000 | 14,322,000 | 129,396,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-114,165,000
Investing CF
$24,137,000
Financing CF
$92,569,000
CapEx
$-1,057,000
Dividends Paid
—
Buybacks
$-1,841,000
EPS Diluted TTM
$-1.12
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,329,206,000
Inventory
$20,245,000
Receivables
$72,044,000
ST Investments
$21,879,000
EBIT TTM
$-147,978,000
Pretax Income TTM
$-157,705,000
Interest Exp TTM
$9,727,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$85,717,000
EBITDA
$-35,359,000
Free Cash Flow
$-100,097,248
Enterprise Value
$2,512,678,400
Total Cash
$38,208,000
Total Debt
$98,345,000
Shares Out
358,035,247
Trailing EPS
$-1.07
Book Value
$0.12
ROE
-837.1%
ROA
-18.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,684,000 | -106,600,000 | -250,642,000 | 155,505,000 | 134,594,000 | 20,911,000 | -87,831,000 |
| Dec 2024 | 3,925,000 | -94,705,000 | -126,235,000 | 145,266,000 | 106,753,000 | 38,513,000 | -68,173,000 |
| Dec 2023 | 6,225,000 | -88,923,000 | -95,904,000 | 151,043,000 | 32,545,000 | 118,498,000 | -66,930,000 |
| Dec 2022 | 26,909,000 | -74,606,000 | 28,317,000 | 215,977,000 | 89,718,000 | 126,259,000 | -65,045,000 |
TTM Snapshot
Revenues TTM
$1,341,000
NetIncome TTM
$-10,547,000
OpCashFlow TTM
$0
Assets (Latest)
$155,505,000
Forward EPS
$-0.22
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $7.81 · call volume: 203 · put volume: 187
Expected Move to 2027-01-15:
±$2.57
(32.91%) —
implied range
$5.24 –
$10.38
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $2.77B | $57.54 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $2.76B | $23.58 | — |
| QURE | uniQure N.V. | $2.71B | $39.11 | — |
| ZLAB | Zai Lab Ltd | $2.88B | $25.69 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.59B | $44.60 | — |
News headlines (Yahoo Finance, 1h cache)
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?
2026-09-29 01:58 · Yahoo
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?
2026-09-26 17:09 · Yahoo
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?
2026-09-25 18:37 · Yahoo
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
2026-09-25 16:11 · Yahoo
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
2026-09-24 14:17 · Yahoo
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
2026-09-28 15:04 · Yahoo
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
2026-09-28 14:45 · Yahoo
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
2026-09-28 14:03 · Yahoo
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
2026-09-25 15:02 · Yahoo
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
2026-09-25 14:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.